China-based biopharmaceutical company Innogen Pharmaceuticals (HKEX: 2591) said on Thursday it has signed an exclusive licensing and commercialisation agreement with Arcera Life Sciences for its internally developed GLP-1 therapy, Efsubaglutide Alfa.
Under the agreement, Arcera will receive exclusive rights to develop and commercialise the product in selected countries across Africa, Eastern Europe, Latin America and the Middle East, while Innogen retains rights in all other markets.
Innogen will receive USD38m in upfront and near-term milestone payments, including a non-refundable upfront payment of USD15m, alongside sales-based milestone payments and tiered royalties of up to double-digit percentages. The companies said the deal has a potential value exceeding USD1bn.
In Innogen's Phase IIb ENLIGHT study in adults with overweight or obesity, participants receiving 20mg once weekly achieved average weight loss of 10.6% after 18 weeks, while those receiving 20mg every two weeks recorded a 9.7% reduction.
The study found improvements in body composition, with the muscle-to-fat ratio increasing by up to 45.3% from baseline and liver fat content declining by up to 51.8% in the once-weekly dosing group. Innogen said the treatment was well tolerated, with no participants discontinuing because of adverse events during the 18-week treatment period.
The company has also completed a Phase II obesity trial in Australia evaluating once-monthly dosing, generating additional clinical data to support future international registration and commercialisation.
The agreement forms part of Innogen's international expansion strategy and marks a further step in the overseas development of Efsubaglutide Alfa.
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
Genentech secures first FDA approval for primary membranous nephropathy treatment